Exametazime
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (April 2008) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
|
|
Exametazime
|
|
| Systematic (IUPAC) name | |
| N-[(3R)-3-[ [3-[ [(2R,3E)-3-Hydroxyiminobutan-2-yl]amino]-2,2-dimethylpropyl]amino]butan-2-ylidene]hydroxylamine | |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C13H28N4O2 |
| Mol. mass | 272.387 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Licence data |
|
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Intravenous |
Exametazime, when used in combination with the radioisotope technetium-99m, is a drug used in the detection of altered regional cerebral perfusion in stroke, and in the localization of intra-abdominal infection and inflammatory bowel disease. It has the brand name Ceretec.
[edit] External links
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
